Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 12, 2008, Pages 1907-1911

  DeRoche, Tom C ^a   Hoschar, Aaron P ^a   Hunt, Jennifer L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MITOSIS RATE; OUTCOME ASSESSMENT; PAROTID GLAND; PLEOMORPHIC ADENOMA; PROTEIN EXPRESSION; SALIVARY GLAND;

ADENOMA, PLEOMORPHIC; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PAROTID NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 57349113282     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Fowler MH, Fowler J, Ducatman B, Barnes L, Hunt JL. Malignant mixed tumors of the salivary gland: a study of loss of heterozygosity in tumor suppressor genes. Mod Pathol. 2006;19:350-355.
2. LiVolsi VA, Perzin KH. Malignant mixed tumors: a clinicopathologic study. Cancer. 1977;39:2209-2230.
3. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol. 2001;32:596-604.
4. Brandwein M, Huvos AG, Dardick I, Thomas MJ, Theise ND. Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:655-664.
5. Felix A, Rosa-Santos J, Mendonça ME, Torrinha F, Soares J. Intracapsular carcinoma ex pleomorphic adenoma: report of a case with unusual metastatic behaviour. Oral Oncol. 2002;38:107-110.
6. Skálová A, Michal M, Ryska A, et al. Oncocytic myoepithelioma and pleomorphic adenoma of the salivary glands. Virchows Arch. 1999;434:537-546.
7. Auclair PL, Ellis GL. Atypical features in salivary gland mixed tumors: their relationship to malignant transformation. Mod Pathol. 1996;9:652-657.
8. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma - a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol. 1994;172:35-44.
9. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamogna P. Salivary duct carcinoma, part II: immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994;78:74-80.
10. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996;27:561-566.
11. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A, Torroba-Caron A, Mendez-Trujillo S, Bermejo-Lopez J. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg. 1997;25:328-334.
12. Skálová A, Stárek I, Kucerová V, Szépe P, Plank L. Salivary duct carcinoma - a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract. 2001;197:621-626.
13. Skálová A, Stárek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2003;42:348-356.
14. Etges A, Pinto DS, Kowalski LP, Soares FA, Araújo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol. 2003;56:914-918.
15. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10:944-946.
16. Kernohan NM, Blessing K, King G, Corbett IP, Miller ID. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol. 1991;163:77-80.
17. Stenman G, Sandros J, Nordkvist A, Mark J, Sahlin P. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer. 1991;3:128-135.
18. Kärjä V, Syrjänen S, Kataja V, Syrjänen K. c-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec. 1994;56:206-212.
19. Müller S, Vigneswaran N, Gansler T, Gramlich T, DeRose PB, Cohen C. c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis. Mod Pathol. 1994;7:628-632.
20. Rosa JC, Félix A, Fonseca I, Soares J. Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation. J Clin Pathol. 1997;50:661-663.
21. Sugano S, Mukai K, Tsuda H, et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope. 1992;102:923-927.
22. Rosa JC, Fonseca I, Félix A, Soares J. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology. 1996;28:247-252.
23. Di Palma S, Skalova A, Vanieek T, Simpson RHW, Starek I, Leivo I. Noninvasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology. 2005;46:144-152.
24. Freitas LL, Araújo VC, Martins MT, Chone C, Crespo A, Altemani A. Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation. Int J Surg Pathol. 2005;13:337-342.
25. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-1038.
26. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-586.
27. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801-806.
28. Nordkvist A, Roijer E, Bang G, et al. Expression and mutation patterns of p53 in benign and malignant salivary gland tumors. Int J Oncol. 2000;16:477-483.
29. Ohtake S, Cheng J, Ida H, et al. Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J Oral Pathol Med. 2002;31:590-597.
30. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol. 2004;15:1319-1329.
31. Tashiro T, Hirokawa M, Harada H, Yokoyama S, Sano T. Cell membrane expression of MIB-1 in salivary gland pleomorphic adenoma. Histopathology. 2002;41:559-567.